NJ3c

NJ3c is a synthetic phenothiazine derivative designed as a dual-target inhibitor of Acetylcholinesterase (AChE) and Monoamine Oxidase B (MAO-B) for the potential treatment of Alzheimer's disease. By inhibiting AChE, NJ3c aims to increase acetylcholine levels to improve cholinergic neurotransmission, while its inhibition of MAO-B is intended to reduce oxidative stress and neuroinflammation associated with the degradation of biogenic amines. Developed by researchers at the JSS Academy of Higher Education and Research, the compound was identified through computational docking and synthesized for in vitro evaluation. Although NJ3c demonstrated high binding affinity and stability toward its targets in silico, preliminary studies indicate mediocre blood-brain barrier permeability, suggesting that future development may require nanoformulation strategies to enhance its central nervous system delivery and therapeutic efficacy.